Items Tagged ‘Incyte Corporation’

November 22nd, 2017

Incyte Announces Initiation of Clinical Trial Evaluating Jakafi® for the Treatment of Essential Thrombocythemia

By

Incyte Corporation announced that the first patient has been treated in the RESET pivotal trial evaluating Jakafi®  (ruxolitinib) compared to anagrelide for the treatment of patients with essential thrombocythemia (ET) who are resistant to or intolerant of hydroxyurea (HU). “We are pleased to treat the first patient in our pivotal trial evaluating ruxolitinib as a […]

View full entry

Tags: essential thrombocythemia, ET, Incyte Corporation, jakafi, Myeloproliferative Neoplasms MPN, News, RESET Clinical Trial, ruxolitinib